S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK train strikes and energy hikes add to a week of turmoil
NIH to fund unproven ALS drugs under patient-backed law
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK train strikes and energy hikes add to a week of turmoil
NIH to fund unproven ALS drugs under patient-backed law
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK train strikes and energy hikes add to a week of turmoil
NIH to fund unproven ALS drugs under patient-backed law
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Russia accused of 'kidnapping' head of Ukraine nuclear plant
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
India launches 5G services, Modi calls it step in new era
New Battery Tech to “Eat Lithium’s Lunch”? (Ad)
UK train strikes and energy hikes add to a week of turmoil
NIH to fund unproven ALS drugs under patient-backed law
NASDAQ:INVA

Innoviva - INVA Stock Forecast, Price & News

$11.61
-0.25 (-2.11%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$11.61
$11.92
50-Day Range
$11.61
$14.79
52-Week Range
$11.56
$20.71
Volume
808,120 shs
Average Volume
640,795 shs
Market Capitalization
$809.33 million
P/E Ratio
9.00
Dividend Yield
N/A
Price Target
$13.00

Innoviva MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
12.0% Upside
$13.00 Price Target
Short Interest
Bearish
15.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.11
Upright™ Environmental Score
News Sentiment
1.08mentions of Innoviva in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-74.61%
From $3.19 to $0.81 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.47 out of 5 stars

Medical Sector

1038th out of 1,093 stocks

Pharmaceutical Preparations Industry

513th out of 547 stocks

INVA stock logo

About Innoviva (NASDAQ:INVA) Stock

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Stock News Headlines

Innoviva Completes Acquisition of La Jolla...
Innoviva (INVA) Misses Q2 Earnings Estimates
See More Headlines
Receive INVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter.

INVA Company Calendar

Last Earnings
7/27/2022
Today
10/02/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INVA
Previous Symbol
NASDAQ:THRX
CUSIP
88338T10
Employees
5
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$13.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+12.0%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$265.85 million
Pretax Margin
60.64%

Debt

Sales & Book Value

Annual Sales
$391.87 million
Cash Flow
$4.54 per share
Book Value
$7.56 per share

Miscellaneous

Free Float
69,086,000
Market Cap
$809.33 million
Optionable
Optionable
Beta
0.48

Social Links


Key Executives

  • Mr. Pavel Raifeld C.F.A. (Age 38)
    Chief Exec. Officer
    Comp: $690.81k
  • Ms. Marianne  Zhen CPAMs. Marianne Zhen CPA (Age 53)
    Chief Accounting Officer & Sec.
    Comp: $462.18k













INVA Stock - Frequently Asked Questions

Should I buy or sell Innoviva stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innoviva in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" INVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INVA, but not buy additional shares or sell existing shares.
View INVA analyst ratings
or view top-rated stocks.

What is Innoviva's stock price forecast for 2022?

2 Wall Street analysts have issued 1-year price objectives for Innoviva's shares. Their INVA share price forecasts range from $13.00 to $13.00. On average, they predict the company's stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 12.0% from the stock's current price.
View analysts price targets for INVA
or view top-rated stocks among Wall Street analysts.

How have INVA shares performed in 2022?

Innoviva's stock was trading at $17.25 at the beginning of the year. Since then, INVA stock has decreased by 32.7% and is now trading at $11.61.
View the best growth stocks for 2022 here
.

When is Innoviva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our INVA earnings forecast
.

How were Innoviva's earnings last quarter?

Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings results on Wednesday, July, 27th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.55 by $0.50. The biotechnology company had revenue of $108.22 million for the quarter, compared to analyst estimates of $103.42 million. Innoviva had a trailing twelve-month return on equity of 28.86% and a net margin of 24.64%.

What other stocks do shareholders of Innoviva own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

What is Innoviva's stock symbol?

Innoviva trades on the NASDAQ under the ticker symbol "INVA."

How do I buy shares of Innoviva?

Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innoviva's stock price today?

One share of INVA stock can currently be purchased for approximately $11.61.

How much money does Innoviva make?

Innoviva (NASDAQ:INVA) has a market capitalization of $809.33 million and generates $391.87 million in revenue each year. The biotechnology company earns $265.85 million in net income (profit) each year or $1.29 on an earnings per share basis.

How can I contact Innoviva?

Innoviva's mailing address is 1350 OLD BAYSHORE HIGHWAY SUITE 400, BURLINGAME CA, 94010. The official website for the company is www.inva.com. The biotechnology company can be reached via phone at (650) 238-9600, via email at investor.relations@inva.com, or via fax at 650-827-8690.

This page (NASDAQ:INVA) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.